Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration and diabetic macular edema. Patients with these conditions are increasingly being prescribed Regeneron Pharmaceuticals' (NASDAQ: REGN) Eylea, and as a result, Eylea's selling at a $6 billion annualized clip globally.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss Eylea's success and how Regeneron Pharmaceuticals' plans to maintain market leadership in these indications in the future.
A full transcript follows the video.
Source: Fool.com
Regeneron Pharmaceuticals Inc. Stock
€880.00
-1.030%
With 34 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 957 € shows a slightly positive potential of 8.75% compared to the current price of 880.0 € for Regeneron Pharmaceuticals Inc..
